The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Tolerability and efficacy of magrolimab plus azacitidine in TP53-mutated AML patients
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the tolerability and efficacy of magrolimab plus azacitidine in TP53-mutated acute myeloid leukemia (AML) patients, highlighting the promising response rates and overall survival, as well as the future role of this combination in the treatment of these patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
